

Amendments to the Claims:

Please cancel Claims 32-40 and 43-77 without prejudice or disclaimer, amend Claims 41 and 42, and add new Claims 78-85 as set forth below.

1-40. (Canceled)

41. (Currently amended) A pharmaceutical composition comprising:

(a) a compound having (i) a selective affinity for the Dopamine-4 (D4) receptor with a pKi value equal to or higher than 8 towards the D4 receptor and less than 8 towards other Dopamine receptors, and (ii) a selective affinity for the 5-HT2A receptor with a pKi value equal to or higher than 8 towards the 5-HT2A receptor and less than 8 towards other 5HT receptors, and

(b) a selective serotonin re-uptake inhibitor,  
as a combined preparation for simultaneous, separate or sequential use for treating a disease or disorder with an underlying dysregulation of emotional functionality which is selected from the group consisting of mood disorders, anxiety disorders, schizophrenia and other psychotic disorders, eating disorders, premenstrual syndrome, somatoform disorders, factitious disorders, dissociative disorders, sexual and gender identity disorders, sleep disorders, adjustment disorders, cognitive disorders, impulse control disorders, pervasive development, attention-deficit and disruptive behaviour disorders, substance-related disorders, personality disorders, psychological factors affecting medical conditions, malingering, antisocial behaviour, bereavement, occupational, identity, phase of life, academic problem, and problems related to abuse or neglect ~~as defined in claim 36.~~

42. (Currently amended) The A pharmaceutical composition according to claim 41 comprising:

(a) pipamperone in a dose ranging between 5 and 15 mg of the active ingredient,  
and

(b) citalopram in a dose ranging between 10 and 40 mg of the active ingredient.

43-77. (Canceled)

78. (New) The pharmaceutical composition according to claim 41, wherein the compound having selective affinity for the Dopamine-4 (D4) receptor and the 5-HT2A receptor is pipamperone.

79. (New) The pharmaceutical composition according to claim 41, wherein the selective serotonin re-uptake inhibitor is citalopram.

80. (New) The pharmaceutical composition according to claim 41, wherein the disease or disorder is a mood disorder.

81. (New) A pharmaceutical composition consisting of:

(a) a compound having (i) a selective affinity for the Dopamine-4 (D4) receptor with a pKi value equal to or higher than 8 towards the D4 receptor and less than 8 towards other Dopamine receptors, and (ii) a selective affinity for the 5-HT2A receptor with a pKi value equal to or higher than 8 towards the 5-HT2A receptor and less than 8 towards other 5HT receptors, and

(b) a selective serotonin re-uptake inhibitor,  
as a combined preparation for simultaneous, separate or sequential use for treating a disease or disorder with an underlying dysregulation of emotional functionality which is selected from the group consisting of mood disorders, anxiety disorders, schizophrenia

and other psychotic disorders, eating disorders, premenstrual syndrome, somatoform disorders, factitious disorders, dissociative disorders, sexual and gender identity disorders, sleep disorders, adjustment disorders, cognitive disorders, impulse control disorders, pervasive development, attention-deficit and disruptive behaviour disorders, substance-related disorders, personality disorders, psychological factors affecting medical conditions, malingering, antisocial behaviour, bereavement, occupational, identity, phase of life, academic problem, and problems related to abuse or neglect.

82. (New) The pharmaceutical composition according to claim 81 consisting of:  
(a) pipamperone in a dose ranging between 5 and 15 mg of the active ingredient,  
and  
(b) citalopram in a dose ranging between 10 and 40 mg of the active ingredient.

83. (New) The pharmaceutical composition according to claim 81, wherein the compound having selective affinity for the Dopamine-4 (D4) receptor and the 5-HT<sub>2A</sub> receptor is pipamperone.

84. (New) The pharmaceutical composition according to claim 81, wherein the selective serotonin re-uptake inhibitor is citalopram.

85. (New) The pharmaceutical composition according to claim 81, wherein the disease or disorder is a mood disorder.